|
CFL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.34040001320557E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.23969999821227E-08 |
| Normal-vs-Stage2 |
1.456920E-03 |
| Normal-vs-Stage3 |
7.14100000243079E-08 |
| Normal-vs-Stage4 |
3.52169999999763E-05 |
| Stage1-vs-Stage2 |
4.491400E-01 |
| Stage1-vs-Stage3 |
4.126400E-01 |
| Stage1-vs-Stage4 |
6.256000E-01 |
| Stage2-vs-Stage3 |
2.250000E-01 |
| Stage2-vs-Stage4 |
3.510400E-01 |
| Stage3-vs-Stage4 |
9.766000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.2891999407193E-10 |
| Normal-vs-AfricanAmerican |
1.047290E-04 |
| Normal-vs-Asian |
3.02080000003091E-06 |
| Caucasian-vs-AfricanAmerican |
6.495800E-01 |
| Caucasian-vs-Asian |
9.688800E-01 |
| AfricanAmerican-vs-Asian |
7.047200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.46500000095673E-08 |
| Normal-vs-Female |
3.68179997600748E-09 |
| Male-vs-Female |
6.053200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.77869999840041E-08 |
| Normal-vs-Age(41-60Yrs) |
2.38380000183724E-08 |
| Normal-vs-Age(61-80Yrs) |
1.198880E-04 |
| Normal-vs-Age(81-100Yrs) |
1.158270E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.662400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.101400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.069000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.871400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.676990E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.481180E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.239900E-02 |
| Classical-VS-Follicular |
1.242390E-03 |
| Classical-VS-Other |
9.136400E-02 |
| Classical-VS-Normal |
3.02119995687633E-10 |
| Tall-VS-Follicular |
1.100410E-03 |
| Tall-VS-Other |
1.528170E-02 |
| Tall-VS-Normal |
7.92980003883059E-09 |
| Follicular-VS-Other |
7.724400E-01 |
| Follicular-VS-Normal |
1.129620E-02 |
| Other-VS-Normal |
3.158400E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.07399999793989E-08 |
| Normal-vs-N1 |
4.224600E-04 |
| N0-vs-N1 |
8.397200E-01 |
|
|
